Oncolytic virus market

Aug 28, 2024

Vaccinia virus-associated oncolytic virus therapies represent a promising approach to cancer treatment, leveraging the ability of the vaccinia virus to selectively infect and destroy cancer cells. The vaccinia virus, historically used in the smallpox vaccine, has been engineered to serve as an oncolytic virus due t...

Aug 14, 2024

Herpes Simplex Virus (HSV)-associated oncolytic virus therapeutics are a promising approach to cancer treatment. These treatments use genetically engineered HSV to target and destroy cancer cells while preserving healthy tissue specifically. The HSV is designed to increase selectively within tumor cells, causing th...

Aug 07, 2024

Adenovirus-associated oncolytic virus therapies represent a promising approach to cancer treatment by harnessing the inherent ability of viruses to selectively infect and destroy cancer cells. These therapies utilize genetically modified adenoviruses, which are engineered to target and replicate specifically within...

Jul 31, 2024

As cancer continues to be a leading cause of mortality worldwide, there is a growing urgency to develop innovative oncolytic virus therapies that can effectively target and eradicate cancer cells. With its unique ability to selectively infect and replicate within tumor cells, oncolytic virus therapy has emerged as ...

Jul 05, 2024

Oncolytic viruses (OVs) represent a new category of cancer treatments that provide several advantages: they selectively replicate within tumor cells, can deliver various eukaryotic transgene payloads, induce immunogenic cell death, enhance antitumor immunity, and generally have a safe profile that doesn't significa...